novel-drug | CARLAT PUBLISHING

MDMA-Assisted Therapy for Severe PTSD

January 31, 2022

Michael Posternak, MD. Dr. Posternak has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

MDMA is being repurposed as part of drug-assisted psychotherapy for PTSD, and this trial will help determine whether it gains FDA approval for that use.

Lybalvi: The Diet Olanzapine

January 31, 2022

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report.

Lybalvi hopes to lower the risk of weight gain on olanzapine by combining it with an opioid blocker (samidorphan). But how does it compare to generic options like metformin and naltrexone?

How to Use SAMe in Clinical Practice

January 4, 2022

Garrett Rossi, MD.

Garrett Rossi, MD. Inpatient/consult attending psychiatrist, AtlantiCare Regional Medical Center, Pomona, NJ. Dr. Rossi has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

SAMe is one of the few natural therapies that can hold its own against antidepressants. In this article, learn when and how to use it.

In the News: Aducanumab (Aduhelm)

November 5, 2021

Rehan Aziz, MD.

Rehan Aziz, MD. Associate professor of psychiatry and neurology, Rutgers Robert Wood Johnson Medical School. Dr. Aziz has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

When the FDA approved aducanumab (Aduhelm) in Alzheimer dementia, the decision came with a heavy dose of controversy. Rehaz Aziz, MD, considers where this novel therapy fits in practice.

In Brief: Meds in the Fast Lane

November 5, 2021

Chris Aiken, MD.

Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC.

In the last five years, more psychotropics have gained approval through the FDA’s expedited pathways than the slow and cautious routes we’ve grown used to. These “fast-track” and “breakthrough therapy” approvals allow drugs to enter the market on the basis of more efficient (ie, smaller) clinical trials.

The Continuing Challenge of Designer Drugs

September 10, 2021

Marilyn A. Huestis, PhD

Marilyn A. Huestis, PhD

Senior fellow at the Institute on Emerging Health Professions, Thomas Jefferson University. Former Chief of the Chemistry and Drug Metabolism Section, IRP, National Institute on Drug Abuse (NIA). Dr. Huestis has disclosed that she has received payment as a consultant for Dynacare Laboratories, which provides lab testing.

Dr. Capurso has reviewed this article and found no evidence of bias in this educational activity.

Designer drugs is a catchall term for a large group of illicit substances that can have disparate effects. Dr. Huestis provides an in depth look at the current state of designer drugs, what clinicians should be wary of, and treatment options.